All In Biotech

Drug Trial Radar · NCT05279859

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies

A Phase 1b/2 Master Protocol of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Hematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Jun 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Mar 15, 2022

Primary completion

Mar 1, 2025

Study completion Jun 1, 2025

Sponsor

Lead sponsor
Erasca, Inc.Industry
Sponsor type
Industry
First posted
Mar 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* To evaluate the safety and tolerability of escalating doses of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with hematologic malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 or ERAS-601 administered in combination with other cancer therapies. * To evaluate the preliminary efficacy of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with hematologic malignancies. * To evaluate the PK profiles of ERAS-007 or ERAS-601 and other cancer therapies when administered in combination.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • ERAS-007Drug

    Administered orally

  • ERAS-601Drug

    Administered orally

  • GilteritinibDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLT)Time frame: Study Day 1 up to Day 29
  2. Maximum Tolerated Dose (MTD)Time frame: Study Day 1 up to Day 29
  3. Recommended Dose (RD)Time frame: Study Day 1 up to Day 29
  4. Adverse EventsTime frame: Assessed up to 24 months from time of first dose

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

  • Texas Oncology

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • NEXT Oncology Virginia

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.